About: Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)
Creator	Wakita, Takaji Watashi, Koichi Tanaka, Yasuhito Ryo, Akihide Matsunaga, Satoko Kanai, Yoshikatsu Nagamori, Shushi Mizokami, Masashi Borroto-Esoda, Katyna Daito, Takuji Iwamoto, Masashi Kusuhara, Hiroyuki Nakajima, Syo Sluder, Ann Sugiyama, Masaya Tsukuda, Senko
Source	Medline; PMC
abstract	Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clinically available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets. Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes. The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin. Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP). We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not. A series of compounds targeting NTCP could inhibit HBV infection. CsA inhibited the binding between NTCP and large envelope protein in vitro. Evaluation of CsA analogs identified a compound with higher anti-HBV potency, having a median inhibitory concentration <0.2 μM. Conclusion: This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatology 2014;59:1726–1737)
has issue date	2014-04-01(xsd:dateTime)
bibo:doi	10.1002/hep.26982
bibo:pmid	24375637
has license	cc-by-nc-nd
sha1sum (hex)	5aaa0dfb49b42f8fab7ce125f89360b828ee9298
schema:url	https://doi.org/10.1002/hep.26982
resource representing a document's title	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)
has PubMed Central identifier	PMC4265264
has PubMed identifier	24375637
schema:publication	Hepatology
resource representing a document's body	covid:5aaa0dfb49b42f8fab7ce125f89360b828ee9298#body_text
is schema:about of	named entity 'CsA' named entity 'binding' named entity 'hepatitis B virus' named entity 'infection' named entity 'differentiated' named entity 'polypeptide' named entity 'transporter' named entity 'cells' named entity 'HBV' named entity 'expressed' named entity 'concentration' named entity 'Evaluation' named entity 'NTCP' named entity 'Cyclosporin A' covid:arg/5aaa0dfb49b42f8fab7ce125f89360b828ee9298 named entity 'inhibited' named entity 'hepatocytes' named entity 'Although' named entity 'cells' named entity 'blockade' named entity 'HBV' named entity 'correlated' named entity 'independent' named entity 'Analogs' named entity 'NTCP' named entity 'reverse transcriptase' named entity 'drug-resistant' named entity 'HBV' named entity 'HBV' named entity 'infection' named entity 'potency' named entity 'HBV' named entity 'infection' named entity 'inhibitory concentration' named entity 'mRNA' named entity 'heparin' named entity 'S3C' named entity 'HBV' named entity 'envelope protein' named entity 'IFN-a' named entity 'infection' named entity 'HCV' named entity 'gene' named entity 'transcription' named entity 'heparin' named entity 'NTCP' named entity 'HBV' named entity 'HBV' named entity 'CsA' named entity 'MDRs' named entity 'cell culture' named entity 'HBV' named entity 'viruses' named entity 'cell surface' named entity 'virus' named entity 'virus strain' named entity 'envelope protein' named entity 'HBV' named entity 'HCV' named entity 'Infection' named entity 'CsA' named entity 'Indirect Immunofluorescence' named entity 'HBV' named entity 'bosentan' named entity 'CsA' named entity 'PerkinElmer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software